<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40278">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031523</url>
  </required_header>
  <id_info>
    <org_study_id>NO.2-20130301</org_study_id>
    <nct_id>NCT02031523</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Kanion Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Kanion Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multi-center, double -blind, placebo -controlled, randomized post-marketing study in
      Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in
      the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sanjie Analgesic Capsule is a Chinese Traditional Patent Medicine. It is a botanical extract
      from the raw materials of the Resina Draconis , Panax Notoginseng, fritillary bulb and coix
      seed, which are derived from a classic prescription of traditional Chinese medicine.

      Sanjie Analgesic Capsule was approved by CFDA in 2004, produced by means of modern
      technology by Jiangsu Kanion Pharmaceutical Co., Ltd. The study is a multi-center, double
      -blind, placebo-controlled, randomized in Chinese subjects with endometriosis-associated
      pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic
      Capsule versus subjects treated with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>dysmenorrhea</measure>
    <time_frame>Baseline, 1,2,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of Symptom (CPP Dyspareunia Defecate-pain Anal-bulge )</measure>
    <time_frame>baseline，1,2,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Signs(Pelvic-tenderness Tubercle )</measure>
    <time_frame>baseline，1,2,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of  Menstrual cycle and quantity</measure>
    <time_frame>baseline，1,2,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of serum CA125</measure>
    <time_frame>baseline,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the size of uterus and endometriosis cyst</measure>
    <time_frame>baseline,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of serum endocrinological hormone</measure>
    <time_frame>baseline,3,4 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
    <description>the content of FSH, LH, E2, PRL, P, T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of SF-36 score</measure>
    <time_frame>Baseline,3 menstrual cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on electrocardiogram, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Baseline,3 menstrual cycle</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on adverse event reports</measure>
    <time_frame>1,2,3 menstrual cycle</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Sanjie analgesic capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sanjie analgesic capsule</intervention_name>
    <description>Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or  follow the doctor's advice.</description>
    <arm_group_label>Sanjie analgesic capsule</arm_group_label>
    <other_name>Jiangsu Kanion Pharmaceutical Co.,Ltd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Jiangsu Kanion Pharmaceutical Co.,Ltd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have a diagnosis of endometriosis by laparoscopy within 5 years prior to
             signing ICF, main complain of dysmenorrhea (or menstrual pain or painful periods) and
             with VAS score of 4 or above; Endometriosis combined with uterine adenomyosis is
             included.

          -  Female between the ages of 18 and 45 years old;

          -  Regular menstrual period, menstrual cycle falls in the ranging from 28 to 30 days;

          -  No pregnancy planning during taking study medication; use (or have their partner use)
             an acceptable method of birth control within the projected duration of the study ;

          -  Subjects must sign ICF and agree for follow up.

        Exclusion Criteria:

          -  Genital cancer or other malignant tumor;

          -  Adnexal masses≥5cm;

          -  Uterine myoma≥3cm;

          -  Suffering from cardiovascular, hepatic, renal or hematopoietic system disease or
             mental illness;

          -  Receiving hormone therapy within 3 months prior to signing ICF;

          -  Receiving surgical treatment for endometriosis within 3 months prior to signing ICF;

          -  Subjects have a plan of pregnancy, being pregnant, breast-feeding during recent 3
             months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lang Jinghe, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Union Medical College Hospital,Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leng Jinhua, M.D.</last_name>
      <email>lengjenny@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Lang Jinghe, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhou Yingfang, M.D.</last_name>
      <email>zhouyf8853@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhou Yingfang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The General Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guan Zheng, Master</last_name>
      <email>GZ9332@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Guan Zheng, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Bin, M.D.</last_name>
      <email>lingbin.ling@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Ling Bin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Obstetrics and Gynecology Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100026</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duan Hua, M.D.</last_name>
      <email>duanhua888@163.com</email>
    </contact>
    <investigator>
      <last_name>Duan Hua, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing ChaoYang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Zhenyu, M.D.</last_name>
      <email>zhengyuzhang2000@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Zhenyu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wang Shixuan, M.D.</last_name>
      <email>sxwang@tjh.tjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wang Shixuan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Xiaoling, M.D.</last_name>
      <email>fxlfxl0510@126.com</email>
    </contact>
    <investigator>
      <last_name>Fang Xiaoling, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shen yang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Shulan, Master</last_name>
      <email>zsl0909@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Shulan, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Shaofen, Bachelor</last_name>
      <email>zhangshaofen@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Shaofen, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Hospital School Of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Jun, Bachelor</last_name>
      <email>linjun@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Lin Jun, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>dysmenorrhea</keyword>
  <keyword>Sanjie analgesic capsule</keyword>
  <keyword>effect/safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dysmenorrhea</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
